Tvardi Therapeutics, Inc.
TVRD Healthcare Biotechnology
In the quarter to June 2026, revenue grew 20.3%, EPS fell 235.3% and free cash flow fell 57.3%, each against the same quarter a year earlier.
Follow TVRD
Tvardi Therapeutics, Inc. (TVRD) EV/Sales
As of 16 October 2026, Tvardi Therapeutics, Inc. (TVRD) trades at a EV/Sales of 4.8×. Over the past ten years it has ranged from −1.8× (February 2024) to 5,735× (March 2017); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 7.0× | — |
| FY2023 | −1.2× | — |
| FY2022 | 11.3× | 215.87% |
| FY2021 | 3.6× | (15.38%) |
| FY2020 | 4.2× | (85.17%) |
| FY2019 | 28.4× | 22.30% |
| FY2018 | 23.2× | (92.48%) |
| FY2017 | 309× | (87.18%) |
| FY2016 | 2,409× | 2,872.94% |
| FY2015 | 81.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 5.8× | (17.58%) |
| Dec 2024 | 7.0× | 189.86% |
| Sep 2024 | 2.4× | 597.70% |
| Jun 2024 | 0.3× | (63.08%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. | 4.8× |
| BCDA BioCardia, Inc. compare | 30.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)